TFMB-(S)-2-HG

CAS No. 1445703-64-9

TFMB-(S)-2-HG( —— )

Catalog No. M34038 CAS No. 1445703-64-9

TFMB-(S)-2-HG (TFMB S 2 HG) is a highly effective inhibitor of TET2, the 5'-methylcytosine hydroxylase. Additionally, it significantly inhibits the EglN prolyl hydroxylases.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 45 In Stock
2MG 29 In Stock
5MG 46 In Stock
10MG 72 In Stock
25MG 149 In Stock
50MG 235 In Stock
100MG 350 In Stock
200MG Get Quote In Stock
500MG 737 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    TFMB-(S)-2-HG
  • Note
    Research use only, not for human use.
  • Brief Description
    TFMB-(S)-2-HG (TFMB S 2 HG) is a highly effective inhibitor of TET2, the 5'-methylcytosine hydroxylase. Additionally, it significantly inhibits the EglN prolyl hydroxylases.
  • Description
    TFMB-(S)-2-HG is a potent inhibitor of the 5'-methylcytosine hydroxylase TET2. TFMB-(S)-2-HG also inhibits the EglN prolyl hydroxylases. TFMB-(S)-2-HG has the potential for the research of acute myeloid leukemia (AML).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    DNA/RNA Synthesis
  • Recptor
    DNA Methyltransferase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1445703-64-9
  • Formula Weight
    288.22
  • Molecular Formula
    C13H11F3O4
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (346.96 mM; Ultrasonic )
  • SMILES
    FC(F)(F)c1cccc(COC(=O)[C@@H]2CCC(=O)O2)c1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Losman JA, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013;339(6127):1621-1625.?
molnova catalog
related products
  • JH-RE-06

    JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing the recruitment of mutagenic POLζ. JH-RE-06 is an effective REV1-REV7 interface inhibitor (IC50=0.78 μM; Kd=0.42 μM), which targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 also improves chemotherapy.

  • COH-29

    A small-molecule inhibitor of ribonucleotide reductase (RNR) that binds to RRM2, interfering with RRM1-RRM2 interactions with IC50 of 16 uM.

  • CX-5461

    CX-5461 is the first potent, selective, orally bioavailable inhibitor of RNA polymerase I.